Filter registries KELA purch., KELA reimb.
Check pre-conditions None
Include endpoints None
Check conditions None
Apply sex-specific rule None
GLP1ANA
Extra metadata
List of similar endpoints to
Glucagon-like peptide-1 (GLP-1) analogues
based on the number of shared cases.
Broader endpoints:
Narrower endpoints:
None
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 11994 | 5297 | 6697 |
| Unadjusted prevalence (%) | 4.61 | 3.60 | 5.92 |
| Mean age at first event (years) | 65.36 | 65.06 | 65.60 |
| Follow-up | Absolute risk | HR [95% CI] | p | N |
|---|---|---|---|---|
| 1998–2019 | 0.07 | 5.10 [4.28, 6.06] | 1.7e-75 | 1133 |
| 15 years | 0.03 | 5.10 [4.28, 6.06] | 1.7e-75 | 1133 |
| 5 years | 0.01 | 6.59 [5.61, 7.73] | <1e-100 | 781 |
| 1 year | 0.00 | 4.43 [3.48, 5.64] | 9.6e-34 | 110 |
Index endpoint: GLP1ANA – Glucagon-like peptide-1 (GLP-1) analogues
GWS hits:
before Glucagon-like peptide-1 (GLP-1) analogues
after Glucagon-like peptide-1 (GLP-1) analogues
Loading survival analyses plot
Loading survival analyses table